Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment of Hepatitis C Clear all
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

NCT01598090
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin, Telaprevir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
28
States / cities
Birmingham, Alabama • Anaheim, California • Garden Grove, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jul 23, 2026, 10:56 AM EDT
Completed No phase listed Observational

Anticipated and Perceived Benefits Following Hepatitis C Treatment

NCT03000023
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Jul 23, 2026, 10:56 AM EDT
Completed No phase listed Observational

Hepatitis C Treatment and Atherosclerosis

NCT00659256
View directory record Official record
Conditions
Chronic Hepatitis C, Atherosclerosis
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
30 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection

NCT02253550
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Peter J. Ruane, M.D.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

NCT00627926
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo
Biological · Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

NCT01353248
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, Tegobuvir, GS-9451, ribavirin tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
42
States / cities
Birmingham, Alabama • Dothan, Alabama • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Jul 23, 2026, 10:56 AM EDT
Terminated Phase 4 Interventional

Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin

NCT00456248
View directory record Official record
Conditions
Hepatitis C
Interventions
Infergen and ribavirin
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Atlanta, Georgia • New Orleans, Louisiana • Harrisburg, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Not applicable Interventional Results available

Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection

NCT02707991
View directory record Official record
Conditions
HIV, Hepatitis C, Chronic
Interventions
Nurse Case Management
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 4 Interventional

Improving Hepatitis C Treatment in Injection Drug Users

NCT00148031
View directory record Official record
Conditions
Hepatitis C, Liver Diseases, Drug Abuse, Alcoholism
Interventions
Pegylated Interferon and Ribavirin, Psychosocial, On-site (MMT Clinic) HCV evaluation and treatment, Off-site HCV evaluation and treatment
Drug · Behavioral
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

NCT01431898
View directory record Official record
Conditions
Hepatitis C
Interventions
GS-9669 tablets, Placebo to Match GS-9669 tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Los Angeles, California • DeLand, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

NCT02607735
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL/VOX, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

NCT00118768
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
valopicitabine, Pegylated Interferon Alfa
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Timeline
Started 2005
U.S. locations
19
States / cities
Phoenix, Arizona • San Diego, California • San Mateo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2009 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

NCT02486406
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin, Ombitasvir mini tablet, Paritaprevir mini tablet, Ritonavir mini tablet, Dasabuvir mini tablet, Ribavirin solution
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

NCT01241760
View directory record Official record
Conditions
Genotype 1 Chronic Hepatitis C, Treatment Naive
Interventions
Ribavirin, Telaprevir, Pegylated interferon alfa-2a
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

NCT00872196
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
ABT-072
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2013 · Synced Jul 23, 2026, 10:56 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

NCT00874796
View directory record Official record
Conditions
HCV Infection
Interventions
GS-9450, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Jul 23, 2026, 10:56 AM EDT
Terminated No phase listed Observational

Clinical Performance Evaluation of DxN HCV Assay

NCT03125408
View directory record Official record
Conditions
Hepatitis C
Interventions
HCV Assay
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Duluth, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

NCT01439373
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GSK2336805, Pegylated interferon alfa-2a, Ribavirin, GSK2336805 Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
9
States / cities
Anaheim, California • Chula Vista, California • Coronado, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Q-Trial in Patients With Hepatitis C

NCT01438320
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Quercetin
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

NCT01200420
View directory record Official record
Conditions
Hepatitis C
Interventions
miravirsen, saline
Drug
Lead sponsor
Santaris Pharma A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Study of SCY-635, Pegasys and Copegus in Hepatitis C

NCT01265511
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Placebo, SCY-635, Pegasys, Copegus
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
San Francisco, California • Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 4 Interventional

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus

NCT00207311
View directory record Official record
Conditions
Fatty Liver, Hepatitis C
Interventions
Xenical, Pegasys, Copegus, Xenicare Program
Drug · Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 4 Interventional Results available

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

NCT02533934
View directory record Official record
Conditions
HIV, Hepatitis C, Cirrhosis
Interventions
Harvoni
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 23, 2026, 10:56 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

NCT04508907
View directory record Official record
Conditions
Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
Interventions
Mavyret
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 23, 2026, 10:56 AM EDT